Arcutis Biotherapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $4.33B
- P/E (TTM)
- 145.0
- Dividend yield
- –
Earnings
Next report expected Oct 27, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 5, 2026 | After market close | $129.90M | $0.11 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 25, 2026 | After market close | $129.50M | $0.13 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 28, 2025 | Before market open | $99.20M | $0.06 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | After market close | $81.50M | $-0.13 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | After market close | $65.85M | $-0.20 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 25, 2025 | After market close | $71.40M | $-0.09 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 6, 2024 | After market close | $44.80M | $-0.33 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | After market close | $30.90M | $-0.42 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 27, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 3, 2023 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 5, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| net product sales | full year 2026 | $525.00M to $540.00M | Raised |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Arcutis Biotherapeutics filed with the SEC
Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · Executive or director change · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Arcutis Announces Chief Financial Officer Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million
Results of operations · EX-99.1 to Form 8-K
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Option Exchange Offer January 11, 2024
Other events · EX-99.1 to Form 8-K
Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Investors Eric McIntyre, Head of Investor Relations [email protected]
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Arcutis has commenced a search for a permanent CCO.
Executive or director change · Other events · EX-99.1 to Form 8-K
Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Arcutis Announces Appointment of Neha Krishnamohan to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Arcutis Announces Second Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
FDA APPROVES ARCUTIS’ ZORYVE™ (ROFLUMILAST) CREAM 0.3% FOR THE
New financial obligation · Other events · EX-99.1 to Form 8-K
19©Copyright 2022. Arcutis Biotherapeutics, Inc. — Presentation designed for an investor audience. ZORYVE Healthcare Provider Payor Patient ZORYVE: Designed to Simplify the Treatment of Psoriasis
New financial obligation · Other events · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
STRATUM Phase 3 Seborrheic Dermatitis Topline Data Presentation June 2022
Other events · EX-99.2 to Form 8-K
Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners
Material agreement · New financial obligation · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K